Root Financial Partners
ADCT icon

Root Financial Partners’s ADC Therapeutics ADCT Stock Holding History

Root Financial Partners’s Portfolio ADCT Stock Details ADCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$10 Buy
+8
New +$9 ﹤0.01% 3805
2026
Q2 		– Sell
-89
Closed -$334 – 447
2026
Q1 		$334 Buy
+89
New +$351 ﹤0.01% 2995

Other funds holding ADCT

ACM
AIGH Capital Management Baltimore, Maryland $992M AUM 516.32% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $85.7B AUM 51.02% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $765B AUM 28.39% 1-Year Est. Return
Sanibel Captiva Trust Company
Sanibel Captiva Trust Company Sanibel, Florida $4.04B AUM 26.09% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return
Russell Investments Group
Russell Investments Group London, United Kingdom $114B AUM 33.83% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $420B AUM 34.97% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $500B AUM 36.84% 1-Year Est. Return

Root Financial Partners's ADCT Position: Q3 2026 in Review

Root Financial Partners opened a new position in ADC Therapeutics (ADCT) in Q3 2026: 8 shares worth $10. The stake represents ﹤0.01% of the portfolio and ranks #3805 among its holdings. This is a return to the name: Root Financial Partners previously reported a position in ADCT as recently as Q1 2026.

Root Financial Partners first reported a position in ADCT in Q1 2026 and has held it in 2 quarters since. The position peaked at $334 in Q1 2026. 47 funds tracked by Wall St. Rank hold ADCT as of Q3 2026.

  • Root Financial Partners held 8 shares of ADC Therapeutics worth $10 as of Q3 2026.
  • ADC Therapeutics was a new Root Financial Partners position in Q3 2026.
  • ADC Therapeutics made up ﹤0.01% of Root Financial Partners's portfolio in Q3 2026, its #3805 holding.
  • Root Financial Partners first reported a position in ADC Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • Root Financial Partners's ADC Therapeutics position peaked at $334 in Q1 2026.
  • 47 funds tracked by Wall St. Rank held ADC Therapeutics as of Q3 2026.

Based on Root Financial Partners's 13F filing for Q3 2026, filed 21 Oct 2026.